NAGE Q2 2021 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+15.8% YoY

Gross Profit

$11M61.1% margin

Operating Income

-$6M-31.4% margin

Net Income

-$6M-31.4% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+20.5%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$66M

Total Liabilities

$24M

Stockholders' Equity

$42M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$15M	+15.8%
Gross Profit	$11M	$9M	+18.9%
Operating Income	-$6M	-$4M	-50.6%
Net Income	-$6M	-$4M	-50.0%